Efficacy of ursodeoxycholic acid in the treatment of patients with chronic hepatitis C

Journal of Gastroenterology and Hepatology

Volumn 10, Issue 4, 1995, Pages 432-437

  LU, CHING‐LIANG ^a   CHAN, CHO‐YU ^a   HWANG, SHINN‐JANG ^a   LU, RUEY‐HWA ^a   LEE, SHOU‐DONG ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

chronic hepatitis C; cytokines; IL 6; TNF ; ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; CYTOKINE; INTERFERON; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029147122     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1995.tb01596.x     Document Type: Article

References (36)

1. Dissolution of cholesterol gallstones by chenocholic acid
2. Ursodeoxycholic acid in primary biliary cirrhosis: Results of a controlled double‐blind trial
3. Effect of ursodeoxycholic acid treatment on alanine aminotransferase and gamma‐glutamyltranspeptidase serum levels in patients with hypertransaminasemia
4. Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis
5. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: A dose‐response study
6. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis
7. Prominent effect of ursodeoxycholic acid on alanine aminotransferase and γ‐glutamyl transpeptidase serum levels in patients with chronic hepatitis
8. Effects of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis
9. + exchange inhibitors
10. Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy
11. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor‐α production by monocytes
12. Ursodiol in the long‐term treatment of chronic hepatitis: A double‐blind multicenter clinical trial
13. Ursodeoxycholic acid and chronic hepatitis C infection
14. Interferon‐alfa with or without ursodeoxycholic acid (UDCA) in the treatment of chronic hepatitis C: Final report of a randomized, controlled, clinical trial (abstract)
15. UDCA as adjuvant therapy in patients not responding to interferon treatment (abstract)
16. Ursodeoxycholic acid (UDCA) treatment in alcoholic patients: Influence of hepatitis C virus infection (abstract)
17. Ursodeoxycholic acid (UDCA) treatment in active cirrhosis with or without hepatitis C antibodies (abstract)
18. Chronic hepatitis: A perspective on classification and determinants of prognosis
19. A randomized controlled clinical trial of recombinant interferon α‐2b in the treatment of acute post‐transfusion hepatitis C: A preliminary report
20. Avoiding false positive with PCR
21. Non‐A, non‐B hepatitis: Evolving epidemiologic and clinical perspective
22. Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: Analysis by detection of anti‐body to hepatitis C virus
23. Treatment of chronic hepatitis C with recombinant interferon alfa: A multicenter randomized, controlled trial
24. Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double‐blind, placebo‐controlled trial
25. High dose of recombinant α‐interferon or γ‐interferon for chronic hepatitis C: A randomized controlled trial
26. Prolonged treatment (18 months) of chronic hepatitis C with recombinant alfa interferon in comparison with a control group
27. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C
28. Beneficial effect of iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon‐α (abstract)
29. Chronic hepatitis C: Issues and problems with current therapy
30. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon‐α
31. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C
32. Interleukin‐6: Histological background, genetics and biological significance
33. Elevated interleukin‐6 levels in sera of patients with fulminant hepatitis
34. Tumor necrosis factor α production by peripheral blood mononuclear cells of patients with chronic liver disease
35. Immunohistochemical studies of intrahepatic tumor necrosis factor α in chronic liver disease
36. Tumor necrosis factor and interleukin 6 in hepatitis C virus infection